Search
Filter Results
Displaying 61–70 of 806 for “retinitis clinical trial”
-
Feb 13, 2024
The free, online event on March 20, 2024, will feature presentations from Rachel Huckfeldt, MD, PhD, Mass Eye and Ear, and Rachelle Lin, OD, Ketchum University.
-
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Apr 12, 2024
Phase 3 Clinical Trial of NAC Launched for RP Patients
The drug is thought to work independent of the mutated gene causing RP.
-
Jan 17, 2019
Pixium's PRIMA Bionic Vision System Restores Central Vision in Dry AMD Clinical Trial
The French bioelectronics company Pixium Vision has reported that its PRIMA bionic vision system has restored some central vision in patients with advanced dry age-related macular degeneration (AMD) participating in a clinical feasibility trial.
-
Apr 28, 2017
jCyte Stem-Cell Therapy Moves into Phase IIb Clinical Trial for RP
Based on lab studies, researchers believe the treatment can preserve and potentially rescue the patient’s existing photoreceptors, thereby saving and possibly restoring vision.
-
Feb 17, 2017
AGTC Leverages Funding from the Foundation to Move Promising Treatments into Clinical Trials
Company Builds on FFB’s Initial Investment to Garner $265 Million in Therapy Development Funding
-
Jul 14, 2022
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
The emerging treatment is gene-agnostic.
-
Jul 25, 2022
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Nov 18, 2020
AGTC Announces Results for Achromatopsia Gene Therapy Clinical Trials
The company will continue enrolling younger patients in higher dosing groups.
-
Apr 8, 2024
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
The emerging treatment is designed to work independent of the patient’s mutated gene.